                         SEQUENCE LISTING

<110>  Glyconova srl
 
<120>  GLCE as a target for anti-tumour therapy

<130>  46250P WO

<160>  8     

<170>  PatentIn version 3.3

<210>  1
<211>  21
<212>  RNA
<213>  Artificial

<220>
<223>  human-specific GLCE-siRNA (sense sequence)

<400>  1
cucgaugaua acaguauggu a                                               21


<210>  2
<211>  21
<212>  RNA
<213>  Artificial

<220>
<223>  human-specific GLCE-siRNA (sense sequence)

<400>  2
uggaaacuua uuacaaaucu a                                               21


<210>  3
<211>  21
<212>  RNA
<213>  Artificial

<220>
<223>  human-specific GLCE-siRNA (sense sequence)

<400>  3
cugggccuau cuguuaacaa a                                               21


<210>  4
<211>  21
<212>  RNA
<213>  Artificial

<220>
<223>  human-specific GLCE-siRNA (sense sequence)

<400>  4
cacaguaaau auguacuugu a                                               21


<210>  5
<211>  19
<212>  RNA
<213>  Artificial

<220>
<223>  mouse-specific GLCE-siRNA (sense sequence)

<400>  5
ggcuuuaugu auucuuuaa                                                  19


<210>  6
<211>  19
<212>  RNA
<213>  Artificial

<220>
<223>  mouse-specific GLCE-siRNA (sense sequence)

<400>  6
gggccuaucu ucuaacgaa                                                  19


<210>  7
<211>  19
<212>  RNA
<213>  Artificial

<220>
<223>  mouse-specific GLCE-siRNA (sense sequence)

<400>  7
cauuugucuc agcaauaaa                                                  19


<210>  8
<211>  18
<212>  RNA
<213>  Artificial

<220>
<223>  mouse-specific GLCE-siRNA (sense sequence)

<400>  8
cgugagcaca ccauuaaa                                                   18


